Bollard Group buys $808,425,699 stake in Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : Bollard Group scooped up 7,727,095 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 33,797,061 shares of Boston Scientific Corporation which is valued at $808,425,699.Boston Scientific Corporation makes up approximately 54.44% of Bollard Group’s portfolio.

Other Hedge Funds, Including , First Quadrant L Pca boosted its stake in BSX in the latest quarter, The investment management firm added 14,100 additional shares and now holds a total of 42,600 shares of Boston Scientific Corporation which is valued at $1,033,476. Boston Scientific Corporation makes up approx 0.02% of First Quadrant L Pca’s portfolio.Sumitomo Life Insurance Co reduced its stake in BSX by selling 29,181 shares or 20.28% in the most recent quarter. The Hedge Fund company now holds 114,734 shares of BSX which is valued at $2,705,428. Boston Scientific Corporation makes up approx 0.36% of Sumitomo Life Insurance Co’s portfolio.Nn Investment Partners Holdings N.v. boosted its stake in BSX in the latest quarter, The investment management firm added 900 additional shares and now holds a total of 8,634 shares of Boston Scientific Corporation which is valued at $204,021.

Boston Scientific Corporation opened for trading at $24.04 and hit $24.45 on the upside on Wednesday, eventually ending the session at $24.26, with a gain of 2.15% or 0.51 points. The heightened volatility saw the trading volume jump to 1,08,68,362 shares. Company has a market cap of $32,918 M.

On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Boston Scientific Corporation was Initiated by Guggenheim to “Buy” on Jun 9, 2016. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Leave a Reply

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.